Insmed Shares Surge 28.40% Amid Key SEC Filings
By ATTN Desk · Editorial oversight: Sean Han
INSMED INC (NASDAQ: INSM)
Introduction
INSMED INC (“Insmed”) is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, focused on developing therapies for serious and rare diseases. Since its incorporation in 1999, Insmed has developed a portfolio that includes inhaled antibiotics, neutrophil-targeted drugs, next-generation therapeutics, and gene therapies.
Corporate Structure
- Headquarters: Bridgewater, NJ (U.S.)
- Global Footprint: Offices in Europe and Japan
- Employees: Approximately 1,000 worldwide
- Leadership: Managed by an experienced team overseeing R&D, regulatory, and commercial efforts
- Core Values: Collaboration, accountability, passion, respect, integrity
Recent Developments
Stock Performance (as of 2025-06-10)
| Metric | Value |
|---|---|
| Share Price | $90.75 |
| Daily Change | +28.40 % |
| Trading Volume | 2,500,919 |
| 52-Week Range | $57.92–$91.86 |
| Market Capitalization (intraday) | $16.29 B |
SEC Filings
- 2025-06-10 (Form 8-K): Current report covering Items 7.01, 8.01, and 9.01
- 2025-06-06 (Form 8-K): Item 8.01 report
- 2025-05-16 (Form S-8): Registration of securities for employee benefit plans
Conferences & Corporate Reports
- 2024 Annual Report: Outlined scientific milestones, workforce expansion, and community initiatives
- Goldman Sachs Healthcare Conference (May 2025): Provided business updates and strategic insights
- BIO 2025 (June 2025): Engaged prospective partners in rare disease innovation
- Global Day of Good (2024): Over 1,000 employees volunteered more than 4,000 hours in various communities
Financial & Strategic Analysis
Key Financial Metrics (Trailing-12 Months)
| Metric | Value |
|---|---|
| Revenue | $381.0 M |
| Net Income | –$1.01 B |
| Profit Margin | –265.93 % |
| Price/Sales | 31.93× |
| Price/Book | 129.83× |
| Total Cash (MRQ) | $1.20 B |
| Total Debt/Equity | 1,316.96 % |
| Beta (5Y Monthly) | 0.79 |
Strategic Initiatives
- Product Pipeline:
- Approved: ARIKAYCE® (amikacin liposome inhalation) for refractory MAC lung disease
- Phase 3:
- ARIKAYCE lifecycle management in MAC
- Brensocatib (DPP1 inhibitor) for non-cystic fibrosis bronchiectasis
- Phase 2: Brensocatib in chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa
- Phase 2: Treprostinil palmitil inhalation powder in PH-ILD and PAH
- Pre-clinical: Gene therapies for Duchenne Muscular Dystrophy (DMD), Amyotrophic Lateral Sclerosis (ALS), Stargardt disease, and Argininosuccinic Aciduria (ASA)
- Patient-Focused Approach: Emphasis on supporting patients and their families facing serious diseases
- Employee Development: Investment in learning opportunities and an inclusive work culture
Market Position & Industry Context
- Therapeutic Focus: Diseases related to rare pulmonary and genetic disorders, utilizing inhaled and gene therapy technologies
- Industry Recognition:
- Ranked as Science’s No. 1 Top Employer (2021–2024)
- Certified as a Great Place to Work® in the U.S. (2021–2025)
- Listed by The Sunday Times as one of the Best Places to Work in the UK (2024, 2025)
- Recognized by BioSpace as one of the Best Places to Work (2025)
- Competitive Landscape:
- Competes with other biopharma companies focused on rare lung infections and inflammatory disorders
- Operates in a regulatory environment shaped by FDA orphan-drug incentives and accelerated approval processes
tl;dr
On 2025-06-10, INSMED’s shares increased by 28.40 % to $90.75 following the filing of two Form 8-Ks (2025-06-10 and 2025-06-06) and a Form S-8 (2025-05-16). The company’s $16.29 B market cap reflects a diverse product pipeline, which includes the approved ARIKAYCE® and ongoing studies on brensocatib, along with preparations for Q2 2025 earnings expected between August 6–11, 2025. Upcoming catalysts involve mid-stage data readouts and new product launches.